---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-110780"
form_type: "8-K"
ticker: "CLPT"
cik: "0001285550"
company_name: "ClearPoint Neuro, Inc."
filed_at: "2026-03-17T23:59:59+00:00"
generated_at: "2026-05-15T10:09:17.298321+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# ClearPoint Neuro reports Q4 revenue $10.4M (+34% YoY); FY 2025 revenue $37.0M (+18%); guides FY 2026 $52-56M

## Summary
- Q4 2025 revenue $10.4M including $1.2M from recent IRRAS acquisition; organic growth 19% YoY.
- Full-year 2025 revenue $37.0M, 11th consecutive year of growth; 14% organic YoY increase.
- 2026 revenue guidance $52-56M, reflecting expected double-digit growth across all four product segments.
- Completed IRRAS acquisition in Nov 2025, adding neurocritical care line and $20M additional financing from Oberland Capital.
- Cash and equivalents $45.9M at Dec 31, 2025, up from $20.1M a year ago.

## SEC filing metadata
- accession: 0001193125-26-110780
- form_type: 8-K
- ticker: CLPT
- cik: 0001285550
- company_name: ClearPoint Neuro, Inc.
- filed_at: 2026-03-17T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1285550/000119312526110780/0001193125-26-110780-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1285550/000119312526110780/clpt-20260317.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-110780
- JSON: https://secwatch.observer/filing/0001193125-26-110780.json
- Plain text: https://secwatch.observer/filing/0001193125-26-110780.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.